好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Natalizumab Reduces Clinical and MRI Disease Activity in Second Line Treatment of Relapsing Remitting Multiple Sclerosis: Results of a Multicenter Study
MS and Related Diseases
(-)
128
Authors/Disclosures
Norman Putzki, MD (Novartis Pharma AG) No disclosure on file
Amanda D. Tomlinson No disclosure on file
Alexander Merkler, MD Dr. Merkler has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for The Neurohospitalist. Dr. Merkler has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for n/a.
Oezguer Yaldizli, MD Dr. Yaldizli has nothing to disclose.
Mathias Maeurer, MD (Universitaetsklinikum) No disclosure on file
Sabine Kuckert No disclosure on file
No disclosure on file
Barbara E. Tettenborn, MD (Kantonsspital St. Gallen) No disclosure on file
Volker Limmroth, MD, PhD (City of Cologne / Cologne General Hospital (Merheim)) No disclosure on file